Stay updated on FLX475 Dose Escalation Trial in Combination With Pembrolizumab
Sign up to get notified when there's something new on the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page.

Latest updates to the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.5%
- Check15 days agoChange DetectedDifference0.4%
- Check22 days agoChange DetectedThe web page has undergone significant updates, including the addition of new identifiers for the clinical trial FLX475-02 and the involvement of collaborators, specifically Merck Sharp & Dohme LLC. Additionally, the revision number has been updated to v2.15.0.SummaryDifference18%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to January 24, 2025.SummaryDifference0.8%
- Check37 days agoChange DetectedThe page has replaced information on Nasopharyngeal Carcinoma with details about Transitional Cell Carcinoma.SummaryDifference0.4%
- Check52 days agoChange DetectedDifference0.5%
Stay in the know with updates to FLX475 Dose Escalation Trial in Combination With Pembrolizumab
Enter your email address, and we'll notify you when there's something new on the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page.